

Paolo Bettica

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10495481/publications.pdf>

Version: 2024-02-01

16
papers

1,002
citations

623734

14
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

1283
citing authors

#	ARTICLE	IF	CITATIONS
1	Muscle histological changes in a large cohort of patients affected with Becker muscular dystrophy. <i>Acta Neuropathologica Communications</i> , 2022, 10, 48.	5.2	11
2	Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. <i>Blood Cancer Journal</i> , 2021, 11, 53.	6.2	24
3	HDAC inhibitors tune miRNAs in extracellular vesicles of dystrophic muscleâ€resident mesenchymal cells. <i>EMBO Reports</i> , 2020, 21, e50863.	4.5	45
4	Histological effects of givinostat in boys with Duchenne muscular dystrophy. <i>Neuromuscular Disorders</i> , 2016, 26, 643-649.	0.6	144
5	Reduced serotonin synthesis and regional cerebral blood flow after anxiolytic treatment of social anxiety disorder. <i>European Neuropsychopharmacology</i> , 2016, 26, 1775-1783.	0.7	16
6	Anxiolytic effects of vestipitant in a sub-group of healthy volunteers known to be sensitive to CO ₂ challenge. <i>Journal of Psychopharmacology</i> , 2014, 28, 491-497.	4.0	10
7	Amygdala-frontal couplings characterizing SSRI and placebo response in social anxiety disorder. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1149-1157.	2.1	29
8	Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. <i>Journal of Psychopharmacology</i> , 2013, 27, 424-434.	4.0	57
9	Preclinical Studies in the mdx Mouse Model of Duchenne Muscular Dystrophy with the Histone Deacetylase Inhibitor Givinostat. <i>Molecular Medicine</i> , 2013, 19, 79-87.	4.4	116
10	Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. <i>Journal of Psychopharmacology</i> , 2012, 26, 1058-1070.	4.0	56
11	Differential Effects of a Dual Orexin Receptor Antagonist (SB-649868) and Zolpidem on Sleep Initiation and Consolidation, SWS, REM Sleep, and EEG Power Spectra in a Model of Situational Insomnia. <i>Neuropsychopharmacology</i> , 2012, 37, 1224-1233.	5.4	84
12	The Orexin Antagonist SB-649868 Promotes and Maintains Sleep in Men with Primary Insomnia. <i>Sleep</i> , 2012, 35, 1097-1104.	1.1	75
13	Amygdala Subregions Tied to SSRI and Placebo Response in Patients with Social Anxiety Disorder. <i>Neuropsychopharmacology</i> , 2012, 37, 2222-2232.	5.4	60
14	Results From 2 Randomized, Double-Blind, Placebo-Controlled Studies of the Novel NK1 Receptor Antagonist Casopitant in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 727-733.	1.4	58
15	Disposition and Metabolism of [14C]SB-649868, an Orexin 1 and 2 Receptor Antagonist, in Humans. <i>Drug Metabolism and Disposition</i> , 2011, 39, 215-227.	3.3	28
16	A Link between Serotonin-Related Gene Polymorphisms, Amygdala Activity, and Placebo-Induced Relief from Social Anxiety. <i>Journal of Neuroscience</i> , 2008, 28, 13066-13074.	3.6	189